102 related articles for article (PubMed ID: 25834916)
61. Clinical commentary: Extra-uterine high-grade serous carcinoma: two pathways, two preventions?
Crum CP; Yoon JY; Feltmate CM
Gynecol Oncol; 2023 Feb; 169():1-3. PubMed ID: 36459857
[No Abstract] [Full Text] [Related]
62. Targeting MAPK in recurrent, low-grade serous ovarian cancer.
Blagden SP
Lancet; 2022 Feb; 399(10324):499-501. PubMed ID: 35123677
[No Abstract] [Full Text] [Related]
63. [Polysaccharides in epithelial mucinous ovarian neoplasms].
Malarewicz A
Ginekol Pol; 1979 Jun; 50(6):527-30. PubMed ID: 225242
[No Abstract] [Full Text] [Related]
64. Ovarian carcinoma; second-look laparotomy postchemotherapy. Preliminary report.
Webster KD; Ballard LA
Cleve Clin Q; 1981; 48(4):365-71. PubMed ID: 6276049
[No Abstract] [Full Text] [Related]
65. MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype.
Gershenson DM; Gourley C; Paul J
J Clin Oncol; 2020 Nov; 38(32):3731-3734. PubMed ID: 32897828
[No Abstract] [Full Text] [Related]
66. An assessment of sequential measurements of immune complex levels in ovarian cancer patients with respect to clinical progress.
Mooney NA; Townsend PA; Wiltshaw E; Evans DG; Shanti-Raju K; Poulton TA
Gynecol Oncol; 1983 Apr; 15(2):207-13. PubMed ID: 6299906
[TBL] [Abstract][Full Text] [Related]
67. Serum alpha-1-proteinase inhibitor with abnormal properties in ovarian cancer.
Thompson S; Wong E; Cantwell BM; Turner GA
Clin Chim Acta; 1990 Dec; 193(1-2):13-25. PubMed ID: 1963579
[TBL] [Abstract][Full Text] [Related]
68. [Future Perspectives in Treatment of Ovarian Cancer].
Fujiwara K
Gan To Kagaku Ryoho; 2016 Feb; 43(2):174-5. PubMed ID: 27093726
[No Abstract] [Full Text] [Related]
69. Pseudomucinous cystadenocarcinoma associated with pregnancy.
WADE ME; JANOVSKI NA; BYSSHE SM
Am J Obstet Gynecol; 1963 Apr; 85():919-25. PubMed ID: 13998170
[No Abstract] [Full Text] [Related]
70. Molecular-targeted therapies for ovarian cancer.
Kigawa J
Int J Clin Oncol; 2012 Oct; 17(5):423. PubMed ID: 22926639
[No Abstract] [Full Text] [Related]
71. E2F1 as a molecular drug target in ovarian cancer.
Farra R; Dapas B; Grassi M; Benedetti F; Grassi G
Expert Opin Ther Targets; 2019 Mar; 23(3):161-164. PubMed ID: 30724632
[No Abstract] [Full Text] [Related]
72. [OVARIAN CANCER. A FOLLOW-UP STUDY OF 35 PATIENTS].
KURZ L
Ugeskr Laeger; 1964 Dec; 126():1640-4. PubMed ID: 14257971
[No Abstract] [Full Text] [Related]
73. Report of a case: Retroperitoneal mucinous cystadenocarcinoma with rapid progression.
Kamiyama H; Shimazu A; Makino Y; Ichikawa R; Hobo T; Arima S; Nohara S; Sugiyama Y; Okumura M; Takei M; Miura H; Namekata K; Tsumura H; Okada M; Takase M; Matsumoto F
Int J Surg Case Rep; 2015; 10():228-31. PubMed ID: 25884614
[TBL] [Abstract][Full Text] [Related]
74. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
[TBL] [Abstract][Full Text] [Related]
75. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
76. Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study.
Kayahashi K; Mizumoto Y; Matsuoka A; Obata T; Iwadare J; Nakamura M; Daikoku T; Fujiwara H
BMC Cancer; 2021 Jan; 21(1):32. PubMed ID: 33413178
[TBL] [Abstract][Full Text] [Related]
77. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer.
Yin M; Li C; Li X; Lou G; Miao B; Liu X; Meng F; Zhang H; Chen X; Sun M; Ling Q; Zhou R
J Surg Oncol; 2011 Jul; 104(1):29-36. PubMed ID: 21416470
[TBL] [Abstract][Full Text] [Related]
78. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
Gurung A; Hung T; Morin J; Gilks CB
Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
[TBL] [Abstract][Full Text] [Related]
79. [Low-grade serous, mucinous carcinoma].
Nakayama K; Kyo S
Gan To Kagaku Ryoho; 2015 Feb; 42(2):179-82. PubMed ID: 25834916
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
